Molecular characterization of a tumor tissue sample was conducted utilizing a 71-gene next-generation sequencing (NGS) panel (Repugene Technology, Hangzhou, People’s Republic of China), identifying rare EGFR L858M (c.2572C > A) and L861R (c.2582T > G) mutations that have been reported to account for 1%–2% of EGFR-positive cases (Figure 1B) (De Pas et al., 2011; Tam et al., 2006). This evidence concerns the gene EGFR and neoplasm.